您的购物车当前为空
Quisovalimab是一种全人源单克隆抗体,特异性结合并中和肿瘤坏死因子超家族成员LIGHT(TNFSF14),从而阻断其与受体的相互作用并抑制T细胞相关炎症反应。Quisovalimab已被用于研究LIGHT介导的炎症通路,在COVID-19相关急性呼吸窘迫综合征(ARDS)及细胞因子释放综合征(CRS)等疾病中具有潜在治疗价值。
别名 奎索利单抗, SAR 252067, MDGN-002, CERC-002, AVTX-002, AEVI 002
Quisovalimab是一种全人源单克隆抗体,特异性结合并中和肿瘤坏死因子超家族成员LIGHT(TNFSF14),从而阻断其与受体的相互作用并抑制T细胞相关炎症反应。Quisovalimab已被用于研究LIGHT介导的炎症通路,在COVID-19相关急性呼吸窘迫综合征(ARDS)及细胞因子释放综合征(CRS)等疾病中具有潜在治疗价值。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 2,490 | 2-4周 | |
| 5 mg | ¥ 6,470 | 2-4周 | |
| 10 mg | ¥ 9,870 | 2-4周 |
TargetMol的所有产品仅用作科学研究或药证申报,不能被用于人体,我们不向个人提供产品和服务。请您遵守承诺用途,不得违反法律法规规定用于任何其他用途。
| 产品描述 | Quisovalimab is a fully human monoclonal antibody that specifically binds to and neutralizes LIGHT(TNFSF14), a member of tumor necrosis factor superfamily, thus blocking its interaction with the receptor and inhibiting T cell-related inflammatory response. Quisovalimab has been used to study the inflammatory pathway mediated by LIGHT, and it has potential therapeutic value in COVID-19-related acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS). |
| 别名 | 奎索利单抗, SAR 252067, MDGN-002, CERC-002, AVTX-002, AEVI 002 |
| 反应种属 | Human |
| 应用 | ELISAFACSFunctional assay |
| 抗体种类 | Monoclonal |
| 缓冲液 | Supplied as a sterile solution in a buffered formulation system (e.g., phosphate-, citrate-, or amino acid-based). Please refer to the CoA for lot-specific composition. |
| 内毒素 | <1.0 EU/mg |
| 同型 | IgG4 (S228P) |
| 推荐同型对照 |
| 偶联 | Unconjugated |
| 靶点 | LIGHT |
| CAS No. | 2427667-03-4 |
| 存储 | Store at low temperature Store at -20°C Shipping with blue ice/Shipping at ambient temperature. 实际储存温度请以COA为准 |
对于不同动物的给药剂量换算,您也可以参考 更多